We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+11.03%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$98.2M
AUM Growth
+$34.1M
Cap. Flow
+$31.2M
Cap. Flow %
31.75%
Top 10 Hldgs %
98.04%
Holding
17
New
6
Increased
7
Reduced
1
Closed
1

Top Buys

1
KALA icon
KALA BIO
KALA
+$12M
2
GARS
Garrison Capital Inc.
GARS
+$6.47M
3
MTEM
Molecular Templates, Inc.
MTEM
+$5.84M
4
JBGS
JBG SMITH
JBGS
+$1.22M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$828K

Top Sells

1
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$300K
2
TMH
Team Health Holdings Inc
TMH
+$174

Sector Composition

1 Healthcare 60.39%
2 Financials 2.25%
3 Real Estate 1.26%
4 Consumer Discretionary 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$38.1M 38.73%
5,514,994
+120,000
+2% +$828K
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$19.4M 19.7%
77,052
+13,869
+22% +$3.42M
KALA icon
3
KALA BIO
KALA
$14.4M
$12.4M 12.65%
+218
New +$12M
AGRX
4
DELISTED
Agile Therapeutics
AGRX
$8.12M 8.26%
910
+98
+12% +$753K
GARS
5
DELISTED
Garrison Capital Inc.
GARS
$7.17M 7.29%
850,000
+781,298
+1,137% +$6.47M
MTEM
6
DELISTED
Molecular Templates, Inc.
MTEM
$7.07M 7.19%
+67,586
New +$5.84M
BRK.B icon
7
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.64M 1.67%
8,945
– –
JBGS
8
JBG SMITH
JBGS
$867M
$1.24M 1.26%
+36,129
New +$1.22M
INDP icon
9
Indaptus Therapeutics
INDP
$337M
$681K 0.69%
+34
New +$490K
ICMB icon
10
Investcorp Credit Management BDC
ICMB
$12.3M
$574K 0.58%
61,859
+6,371
+11% +$63K
ONCT
11
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$531K 0.54%
+449
New +$404K
ADNT icon
12
Adient
ADNT
$1.55B
$398K 0.41%
4,737
– –
TMH
13
DELISTED
Team Health Holdings Inc
TMH
$335K 0.34%
7,709
-4
-0.1% -$174
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.5B
$306K 0.31%
1,997
+7
+0.4% +$1.06K
ACRS icon
15
Aclaris Therapeutics
ACRS
$793M
$263K 0.27%
10,176
+38
+0.4% +$1.02K
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$95K 0.1%
+4,050
New +$45.4K
PRTK
17
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-12,456
Closed -$300K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2017 Portfolio in Review

As of Q3 2017, Caxton Corporation held 17 positions worth $98.2M, up 53% from $64.1M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caxton Corporation deployed $31.2M of net new capital in Q3 2017, opening 6 new positions and adding to 7 existing holdings. Its largest new stake was KALA BIO: 218 shares worth $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 62% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was Team Health Holdings Inc, an estimated $174 trimmed.

  • Caxton Corporation's largest Q3 2017 buy was KALA BIO: 218 shares worth $12.4M.
  • Caxton Corporation added most to Garrison Capital Inc. in Q3 2017, an estimated $6.47M increase.
  • Caxton Corporation's biggest Q3 2017 reduction was Team Health Holdings Inc, cutting an estimated $174.
  • Caxton Corporation fully exited Paratek Pharmaceuticals, Inc. in Q3 2017, selling an estimated $300K.
  • Caxton Corporation's ten largest holdings make up 98% of its $98.2M portfolio in Q3 2017.
  • Caxton Corporation opened 6 new positions and closed 1 in Q3 2017.
  • Caxton Corporation's portfolio value rose 53% quarter-over-quarter to $98.2M.

Based on Caxton Corporation's 13F filing for Q3 2017, filed 14 Nov 2017.